Jordan Elm to Antiparkinson Agents
This is a "connection" page, showing publications Jordan Elm has written about Antiparkinson Agents.
Connection Strength
0.964
-
Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience. Mov Disord. 2007 Apr 30; 22(6):822-7.
Score: 0.289
-
BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease. Neurotherapeutics. 2020 10; 17(4):1785-1795.
Score: 0.185
-
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93.
Score: 0.124
-
Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort. J Parkinsons Dis. 2015; 5(4):773-82.
Score: 0.123
-
Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. Parkinsonism Relat Disord. 2010 Sep; 16(8):507-12.
Score: 0.090
-
The impact of depressive symptoms in early Parkinson disease. Neurology. 2007 Jul 24; 69(4):342-7.
Score: 0.073
-
Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology. 2006 Mar 14; 66(5):628-33.
Score: 0.067
-
Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18.
Score: 0.015